Fortrea to Acquire Worldwide Clinical Trials’ Early Phase Unit
DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Fortrea has entered into a definitive agreement to acquire...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Fortrea has entered into a definitive agreement to acquire...
MARLBOROUGH, Mass., June 1, 2026 SCIEX, a Danaher company and global leader in life science analytical technologies, has unveiled...
HOUSTON, June 1, 2026 Iterion Therapeutics has unveiled compelling clinical data supporting tegavivint, its first-in-class Wnt/β-catenin pathway inhibitor, as...
SANTA CLARA, Calif., June 1, 2026 Agilent Technologies and Sound Analytics have announced a strategic collaboration aimed at transforming...
